Dose Insider / Glossary / Orforglipron

OrforglipronWhat the molecule is and what its trials showed

Updated November 20, 2026 路 3 min read 路 ATTAIN-1 (NEJM 2025), phase 2 (NEJM 2023), FOUNDAYO label

Orforglipron is a GLP-1 receptor agonist that is not a peptide: a small molecule, taken by mouth once a day, that activates the same receptor as semaglutide and tirzepatide. Eli Lilly developed it, and it was approved in the United States in 2026 under the brand name Foundayo for weight management.

11.2%36 mg in the trial, weight lost by week 72
Weight lost by week 72ATTAIN-1, adults with obesity, % of weight36 mg in the trial11.2%12 mg in the trial8.4%6 mg in the trial7.5%Placebo2.1%Weight lost by week 72ATTAIN-1, adults with obesity, % of weight36 mg in the trial11.2%12 mg in the trial8.4%6 mg in the trial7.5%Placebo2.1%

The label reports these as Foundayo 17.2, 9 and 5.5 mg.

On this page

In its main phase 3 trial, ATTAIN-1, adults with obesity lost 11.2% of their weight over 72 weeks on the highest dose, against 2.1% on placebo.1,2

Why a small molecule matters

Every earlier GLP-1 medicine is a peptide, a chain of amino acids modeled on the hormone. Peptides are broken down in the gut, which is why most are injected and why the semaglutide tablets need an absorption enhancer, an empty stomach and a 30-minute wait, and still absorb only 1% to 2% of the dose.3 The phase 2 report calls orforglipron a nonpeptide GLP-1 receptor agonist, and the ATTAIN-1 report an oral small-molecule one.1,4 On the Foundayo label, about 77% of a 0.8 mg dose reaches the blood, food has no clinically relevant effect, and the molecular weight is 902.0, against 4,113.58 for semaglutide.2,5

The phase 2 trial

The 2023 phase 2 trial enrolled 272 adults who started at an average of 108.7 kg. At week 36, weight fell by 9.4% to 14.7% across the dose groups, against 2.3% on placebo, and 46% to 75% lost at least 10%, against 9%. Stomach and gut events were the most common, mostly mild to moderate and mainly during the dose climb, and led 10% to 17% to stop the drug.4

ATTAIN-1, the phase 3 trial

ATTAIN-1 enrolled 3,127 adults with obesity and without diabetes and gave them orforglipron 6 mg, 12 mg or 36 mg, or placebo, once a day for 72 weeks, alongside diet and activity advice.1

The trial used an investigational formulation. The Foundayo label reports the same trials as the equivalent Foundayo doses of 5.5, 9 and 17.2 mg and, in its own analysis, gives weight losses of 7.4%, 8.3% and 11.1%.2 Waist size, systolic blood pressure, triglycerides and non-HDL cholesterol also improved against placebo. ATTAIN-1 was funded by Eli Lilly.1

A second trial, ATTAIN-2, tested the drug in 1,613 adults with type 2 diabetes and a body mass index of 27 or more. On the label's equivalent doses, weight fell by 5.1%, 7.0% and 9.6% over 72 weeks, against 2.5% on placebo, smaller losses than without diabetes, as with the other GLP-1 medicines.2,6

Next to the other weight medicines

The weight loss is smaller than in the label trials of the weekly injections, 14.9% on Wegovy 2.4 mg and 20.9% on Zepbound 15 mg, and than the 13.6% on the Wegovy 25 mg tablet.3,7 None of those was tested against orforglipron in the sources we read. What orforglipron offers instead is convenience: a pill taken once a day with or without food.2

Safety in brief

The Foundayo label carries the same boxed warning about thyroid C-cell tumors seen in rodents as the injected GLP-1 medicines. It also notes that orforglipron is broken down mainly by the liver enzyme CYP3A4, so some other medicines change its dose limits.2 Our page on nausea on a GLP-1 covers the most common side effect.

Sources

  1. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. Funded by Eli Lilly. doi:10.1056/NEJMoa2511774
  2. FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly and Company; DailyMed, version published August 13, 2026; boxed warning and sections 1, 2, 11, 12 and 14. dailymed.nlm.nih.gov
  3. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 12.3 and 14. accessdata.fda.gov
  4. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 2023;389:877-888. doi:10.1056/NEJMoa2302392
  5. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 11. accessdata.fda.gov
  6. ClinicalTrials.gov record NCT05872620 (ATTAIN-2), sponsor Eli Lilly and Company; read November 20, 2026. clinicaltrials.gov
  7. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov

Related analyses

Log each tablet and see your doses, weight and symptoms together.

Open Dose Insider